↑ トップへ　← 戻る

299. 嚢胞性線維症
［臨床試験数：1,592，薬物数：1,539（DrugBank：255），標的遺伝子数：81，標的パスウェイ数：162］

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2009-009869-34-SE
(EUCTR)		12/10/200929/07/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122United Kingdom;Germany;Spain;Sweden
2EUCTR2009-009869-34-GB
(EUCTR)		02/09/200909/04/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122Germany;United Kingdom;Spain;Sweden
3NCT00910351
(ClinicalTrials.gov)		July 200928/5/2009Cipro Inhaler for Cystic Fibrosis Children Ages 6-12A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry PowderPseudomonas InfectionDrug: Ciprofloxacin (Cipro, BAYQ3939)BayerNULLCompleted6 Years12 YearsBoth19Phase 1United States
4EUCTR2009-009869-34-DE
(EUCTR)		08/06/200917/03/2009Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis - Bayq3939 Idiopathic and post-pneumonic non-Cystic Fibrosis Bronchiectasis in pulmonary stable patients (defined as FEV1 of > 35 % and < 80 percent of predicted)
MedDRA version: 9.1;Level: LLT;Classification code 10006445;Term: Bronchiectasis
MedDRA version: 9.1;Level: PT;Term: Bronchiectasis		Product Name: Cipro Inhale
Product Code: BAYq3939
INN or Proposed INN: Ciprofloxacin		Bayer HealthCare AGNULLNot RecruitingFemale: yes
Male: yes		122Spain;Germany;United Kingdom;Sweden
5NCT00930982
(ClinicalTrials.gov)		June 200930/6/2009Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis BronchiectasisRandomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis BronchiectasisBronchiectasisDrug: Ciprofloxacin (Cipro, BAYQ3939);Drug: PlaceboBayerNovartisCompleted18 YearsN/AAll124Phase 2United States;Australia;Germany;Spain;Sweden;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT00645788
(ClinicalTrials.gov)		May 200826/3/2008Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic FibrosisRandomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic FibrosisCystic FibrosisDrug: Ciprofloxacin (Cipro Inhale, BAYQ3939);Drug: PlaceboBayerNovartisCompleted12 YearsN/AAll288Phase 2United States;Australia;Canada;Denmark;Germany;Israel;Norway;Sweden;United Kingdom

先頭へ